Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
October 4, 2017
End Date
September 30, 2022
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
October 4, 2017
End Date
September 30, 2022